ProQR Therapeutics (PRQR) Cash from Operations (2013 - 2026)
ProQR Therapeutics (PRQR) posted quarterly Cash from Operations of 13046645.72 for Q1 2026, up 29.99% year-on-year from 10036729.94 in Q1 2025, and up 24.34% on a QoQ basis from 17243421.07 in Q4 2025.
ProQR Therapeutics (PRQR) Cash from Operations (2013 - 2026) Analysis & Trends
ProQR Therapeutics (PRQR) has reported Cash from Operations for 14 consecutive years, with 13046645.72 the latest figure, recorded in Q1 2026.
- Quarterly Cash from Operations rose 29.99% year-over-year to 13046645.72 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 57809214.93 (down 24.1% YoY) and the FY2025 annual result came in at 62117509.8, down 39.71% from the prior year.
- Cash from Operations improved to 13046645.72 in Q1 2026 per PRQR's latest filing, from 17243421.07 in the prior quarter.
- Over the last five years, Cash from Operations for PRQR reached as high as 50690173.01 in Q1 2023 and fell as low as 23290510.07 in Q1 2022.
- A 5-year average of 10296946.57 and a median of 13685038.07 in 2024 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations slumped 510.71% — and 2023, when it jumped 317.64%.
- Year by year, Cash from Operations stood at 20293138.52 in 2022, then soared by 79.97% to 4064772.66 in 2023, then tumbled by 236.67% to 13685038.07 in 2024, then declined by 26.0% to 17243421.07 in 2025, then rose by 24.34% to 13046645.72 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 13046645.72, 17243421.07, and 13922870.51 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | ProQR Therapeutics | 219.53 Mn | 175.72 Mn | - | -13.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.05 Mn |
| Mar 31, 2026 | -13.05 Mn |
| Dec 31, 2025 | -17.24 Mn |
| Dec 31, 2025 | -17.24 Mn |
| Sep 30, 2025 | -13.92 Mn |
| Sep 30, 2025 | -13.92 Mn |
| Jun 30, 2025 | -13.60 Mn |
| Jun 30, 2025 | -13.60 Mn |
| Mar 31, 2025 | -18.64 Mn |
| Mar 31, 2025 | -18.64 Mn |
| Dec 31, 2024 | -13.69 Mn |
| Dec 31, 2024 | -13.69 Mn |
| Sep 30, 2024 | -6.44 Mn |
| Sep 30, 2024 | -6.44 Mn |
| Jun 30, 2024 | -7.82 Mn |
| Jun 30, 2024 | -7.82 Mn |
| Mar 31, 2024 | -17.22 Mn |
| Mar 31, 2024 | -17.22 Mn |
| Dec 31, 2023 | -4.06 Mn |
| Dec 31, 2023 | -4.06 Mn |